These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 27982318)

  • 1. Association of oxidative stress and DNA damage with grafting time in patients with multiple myeloma and lymphoma submitted to autologous hematopoietic stem cell transplantation.
    Santos TN; Duarte FB; Maia Filho PA; Santos TE; Barbosa MC; Almeida Filho TP; Cavalcanti BC; Vasconcelos PR; Dutra LL; Lopes GS; Costa FO; Leitão JP; KauFman J; AraúJo BS; Barroso KS; Lemes RP
    Rev Assoc Med Bras (1992); 2016 Oct; 62 Suppl 1():39-43. PubMed ID: 27982318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma.
    Auner HW; Sill H; Mulabecirovic A; Linkesch W; Krause R
    Ann Hematol; 2002 Jul; 81(7):374-7. PubMed ID: 12185506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
    Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
    Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Cryopreserved Peripheral Blood Stem Cell Graft for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma and Lymphoma Patients.
    Noiperm P; Julamanee J; Viboonjuntra P; Lekhakula A
    Ann Transplant; 2023 Jan; 28():e938595. PubMed ID: 36647325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma.
    Graff TM; Singavi AK; Schmidt W; Eastwood D; Drobyski WR; Horowitz M; Palmer J; Pasquini M; Rizzo DJ; Saber W; Hari P; Fenske TS
    Bone Marrow Transplant; 2015 Jul; 50(7):947-53. PubMed ID: 25867651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rate of long-term survival for high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy.
    Espigado I; Ríos E; Marín-Niebla A; Carmona M; Parody R; Pérez-Hurtado JM; Márquez FJ; Urbano-Ispizua A
    Transplant Proc; 2008 Nov; 40(9):3104-5. PubMed ID: 19010208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hodgkin's Lymphoma - evaluation of patients submitted to Autologous transplantation of hematopoietic cells in the Hematology Service of the Hospital Walter Cantídio - Fortaleza, Brazil.
    Duarte FB; Fernandes MG; Kaufmann J; Barroso KS; Leitão JP; Araujo BS; Costa CM; Quixadá-Medica AT; Holanda JS; Landim SV; Pitombeira MH
    Rev Assoc Med Bras (1992); 2016 Oct; 62 Suppl 1():34-38. PubMed ID: 27982313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
    Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk and use of conicity index in patients submitted to autologous hematopoietic stem cell transplantation.
    Morais SR; Viana ACC; Daltro AFCS; Mendonça PDS
    Einstein (Sao Paulo); 2018 Jun; 16(2):eAO4253. PubMed ID: 29898091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival.
    Dean R; Masci P; Pohlman B; Andresen S; Serafino S; Sobecks R; Kuczkowski E; Curtis J; Maciejewski J; Rybicki L; Kalaycio M; Hsi E; Theil K; Bolwell BJ
    Bone Marrow Transplant; 2005 Dec; 36(12):1049-52. PubMed ID: 16247431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome.
    Gil L; Styczynski J; Komarnicki M
    Infection; 2007 Dec; 35(6):421-7. PubMed ID: 17926001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both.
    Langenmayer I; Weaver C; Buckner CD; Lilleby K; Appelbaum FR; Longin K; Rowley S; Storb R; Singer J; Bensinger WI
    Bone Marrow Transplant; 1995 Feb; 15(2):241-6. PubMed ID: 7773213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
    Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
    J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Società Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey.
    Pierelli L; Berto P; Accorsi P; Milone G; Lopatriello S; Aiello A; Iacopino P; Olivieri A; Rambaldi A; Bosi A
    Transfus Apher Sci; 2013 Dec; 49(3):615-22. PubMed ID: 23973731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation.
    Baron F; Gothot A; Salmon JP; Hermanne JP; Pierard GE; Fillet G; Beguin Y
    Br J Haematol; 2000 Dec; 111(3):745-53. PubMed ID: 11122133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous Hematopoietic Stem Cell Transplantation-10 Years of Data From a Developing Country.
    Ali N; Adil SN; Shaikh MU
    Stem Cells Transl Med; 2015 Aug; 4(8):873-7. PubMed ID: 26032748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
    Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
    Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Difference in costs of autologous transplantation of peripheral and bone marrow hematopoietic stem cells. A retrospective analysis over 1 year of transplantation in lymphoma, Hodgkin's disease and myeloma in a Center].
    Rio B; Marjanovic Z; Belhocine R; Vekhoff A; Andrieu V; Klaren J; Boccaccio C; Delmer A; Ajchenbaum-Cymbalista F; Hunault M; Bazarbachi A; Lévy V; Andreu G; Zittoun R
    Ann Med Interne (Paris); 1996; 147(5):313-9. PubMed ID: 9033732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.